Moreover, this study showed that a combination of linsitinib and the second-generation PI carfilzomib, which is commonly used in relapsed/refractory MM and which, to our knowledge, has not been investigated in functional or clinical studies in the context of IGF1R so far, was effective in six out of seven HMCLs. The gene discussed is IGF1R; the disease is Miyoshi myopathy.